---
layout: default
title: Abacavir Sulfate
parent: 僅模型預測 (L5)
nav_order: 11
evidence_level: L5
indication_count: 0
---

# Abacavir Sulfate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ABACAVIR SULFATE: Repurposing Readiness Assessment — Insufficient Data to Complete Full Evaluation

---

## One-Sentence Summary

Abacavir Sulfate is a nucleoside reverse transcriptase inhibitor (NRTI) widely used in HIV-1 treatment regimens.
The current Evidence Pack contains **no TxGNN-predicted new indications**, and critical data elements — including mechanism of action, package insert warnings, and product-level registration details — are missing.
With **6 active registrations** confirmed in Malaysia but no repurposing candidates generated, this evaluation cannot proceed beyond a preliminary readiness assessment.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not retrieved (license details unavailable) |
| Predicted New Indication | No prediction available |
| TxGNN Prediction Score | Not available |
| Evidence Level | N/A |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 6 |
| Recommended Decision | **Hold** |

---

## Why Is This Prediction Reasonable?

No repurposing candidates were returned by the TxGNN model in this evaluation run. Without a predicted new indication, mechanistic bridging analysis between an original and a target disease cannot be performed.

Furthermore, mechanism of action (MOA) data is listed as a data gap (DG002), which means even a manual mechanistic rationale cannot be constructed at this stage. Abacavir's pharmacological class is known from the literature to be NRTI, but a formal MOA profile from DrugBank has not been retrieved and should not be substituted with assumptions.

Until the prediction pipeline is re-run with a complete drug entry (including a valid DrugBank ID) and MOA data is retrieved, this section will remain incomplete.

---

## Malaysia Market Information

Six registrations are confirmed by the NPRA query (query ID 1, status: success), but product-level details — including authorization numbers, product names, dosage forms, and approved indication text — were not populated in the current Evidence Pack. The table below reflects what is available.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------------------|-------------|-------------|-------------------|
| — | — | — | Details not retrieved; 6 registrations confirmed via NPRA |

> **Action required:** Re-query NPRA with full license retrieval to populate product details before proceeding to clinical review.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** Key warnings and contraindications are listed as blocking data gaps (DG001). A known class-specific concern for abacavir is HLA-B\*5701-associated hypersensitivity syndrome — this should be explicitly captured when package insert data is retrieved and must be addressed in any prospective repurposing protocol.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack lacks predicted indications, a valid DrugBank ID, MOA data, and package insert safety information — the minimum inputs required for a repurposing evaluation. Proceeding without these would produce an unreliable result.

**To proceed, the following is needed:**

- **TxGNN prediction pipeline**: Re-run with a resolved DrugBank ID for Abacavir Sulfate to generate repurposing candidates
- **DrugBank ID resolution**: Map "ABACAVIR SULFATE" to its DrugBank entry (expected: DB01048) via the DrugBank API
- **MOA data retrieval** (DG002): Query DrugBank for mechanism of action, pharmacodynamics, and drug targets
- **Package insert retrieval** (DG001 — Blocking): Download and parse the NPRA/TFDA package insert PDF to extract warnings, contraindications, and special population guidance
- **NPRA license details**: Re-query NPRA to populate authorization numbers, product names, dosage forms, and approved indication text for all 6 registrations
- **HLA-B\*5701 screening policy**: Confirm whether Malaysia's current clinical guidelines mandate pre-treatment genotyping, as this is a material safety guardrail for any repurposing study design
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

